ClinicalTrials.gg
CompletedNCT03607539Updated May 11, 2026Results posted

Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC

A Phase 3 interventional study of Sintilimab and Pemetrexed in Lung Neoplasms, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
397
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing sintilimab in Lung Neoplasms — 5 open to participants now, 5 under way, none of them phase 3. sintilimab · Lung Neoplasms.

Enrollment
Largest of 12
397 · median 30
Started
2018
with 1 other
Phase 3
Only one
of the 12
Registered
1st of 12
by date
Lead sponsor
1 of 12
Innovent Biologics (Suzhou) Co. Ltd.

Among the 12 studies testing sintilimab in Lung Neoplasms, this one has the largest enrollment, is one of 2 that started in 2018, is the only one in phase 3, and was the 1st registered.

Lung Neoplasms

5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

5 of the 12 studies testing sintilimab in Lung Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About sintilimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing sintilimab in Lung Neoplasms, or all of them as a file.
02

Study summary

Efficacy and Safety Evaluation of IBI308 in Patients with advanced or metastatic Non-squamous NSCLC

Read the detailed description

Sintilimab is expected to increase the PFS from 6 months to 9.2 months. Anti-PD-1 therapy in Chinese non-squamous NSCLC naïve patients will be investigated in this clinical trial.

Additionally the correlation between PD-L1 expression and the response to Sintilimab treatment in Chinese non-squamous NSCLC as well as the role of iRECIST in immune checkpoint inhibitor treatment evaluation will also be assessed.

03

Conditions studied

  • Lung Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign written before any trial-related processes are implemented;
  2. Age ≥ 18 years and \<75 years;
  3. exceeds 3 months;
  4. The investigator confirmed at least one according to 1.1.

    A measurable lesion located in the field of previous radiation therapy or after local treatment may be selected as a target lesion if it is confirmed to have progressed;

  5. According to the International Lung Cancer Research Association and the American Association for the Classification of Cancer Classification, the 8th edition of the TNM (Tumor Node ) staging of lung cancer, a or cytologically confirmed locally advanced (IIIB/IIIC phase) that cannot be treated surgically and cannot undergo radical concurrent chemoradiotherapy, Patients with metastatic or recurrent (stage IV) non-squamous NSCLC;
  6. Confirmed for patients with EGFR (Epidermal growth factor receptor) or ALK (Anaplastic lymphoma kinase) targeted therapy (documentary evidence of no tumor EGFR-sensitive mutations and no ALK gene rearrangement)
  7. The Eastern Cancer Cooperative Group () has a performance score of 0 or 1;
  8. Have not received any systematic anti-tumor treatment for advanced disease; The patient may have received chemotherapy as long as the disease relapses at least 6 months after the last dose of chemotherapy is completed;
  9. Adequate hematologic function, defined as ≥1.5×10\^9 /L, count ≥100 ×10\^9 /L, ≥9g/dL (no blood transfusion or erythropoietin (EPO) within 7 days) Dependency);
  10. Adequate liver function, defined as total levels ≤ 1.5 times normal upper limit () and (AST) and alanine aminotransferase (ALT) levels ≤ 2.5 times ULN in all patients, or for recorded liver Patients with metastasis, AST and ALT levels ≤ 5 times ULN;
  11. Adequate renal function, defined as serum creatinine ≤ 1.5 times ULN or measured or calculated ≥ 60 ml / min (Cockcroft-Gault formula);
  12. Coagulation function is adequate, defined as (INR) or prothrombin time (PT) ≤ 1.5 times normal upper limit (ULN); if the subject is receiving anticoagulant therapy, as long as the PT is used in anticoagulant drugs Within the scope;
  13. Female subjects of childbearing age should be negative for urine or serum pregnancy test within 72 hours prior to the first study drug administration (Day 1, Day 1). If the urine pregnancy test results are positive or cannot be confirmed as negative, a blood pregnancy test is required.
  14. If there is a risk of conception, male and female patients are required to use high-efficiency (ie, an annual failure rate of less than 1%) and continue until at least 180 days after stopping the trial treatment; Note: If abstinence is the usual lifestyle of the subject and the preferred method of contraception, abstinence can be accepted as a method of contraception.

Exclusion criteria

Exclusion criteria:

  1. Histological squamous cell-dominated NSCLC; Mixed cell types must distinguish between dominant cell morphology, and if small cell types are present, the subject is not eligible for inclusion;
  2. Currently participating in interventional clinical research or treatment, or receiving other research drugs or using research equipment within 4 weeks before the first dose;
  3. Previously received the following therapies: , anti-PD-L1 or anti-PD-L2 drugs or against another stimulatory or synergistic inhibition of T cell receptors [eg CTLA-4 (Cytotoxic T lymphocyte antigen-4), OX-40 (also called CD134, cluster of differentiation134), CD137] agent;
  4. Received a traditional Chinese medicine with anti-tumor effect, or an immunomodulatory drug (thymosin, interferon, interleukin) within 2 weeks before the first dose, or received major surgery within 3 weeks before the first dose;
  5. Pulmonary radiation therapy of >30 Gy within 6 months prior to the first dose;
  6. Completed palliative radiotherapy within 7 days prior to the first dose;
  7. Clinical active diverticulitis, abdominal abscess, gastrointestinal obstruction and peritoneal ;
  8. Have received a physical organ or blood system transplant;
  9. There is clinically uncontrollable pleural effusion/peritoneal effusion;
  10. known to have severe allergic reactions (≥3 grade) to the active ingredients of Sintilimab, pemetrexed, cisplatin, carboplatin and or any ;
  11. Active diseases requiring systemic treatment (eg, using a disease-modifying drug, or ) within 2 years prior to the first dose. Alternative therapies (such as thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) are not considered systemic treatments;
  12. Diagnosis of immunodeficiency or study of systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study.

    Physiological doses of corticosteroids (≤10 mg/day of prednisone or equivalent) are permitted;

  13. Has not fully recovered from the toxicity and/or complications caused by any intervention before starting treatment (ie, ≤1 or reaching baseline, excluding fatigue or alopecia);
  14. Other malignant tumors were diagnosed within 5 years prior to the first dose, with the exception of radical cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, and/or radically resected carcinoma in situ;
  15. Active central nervous system (CNS) metastasis and / or cancerous meningitis. Patients with treated who have remained clinically stable for at least 2 weeks and have no new or advanced brain metastases may be enrolled and discontinued hormone therapy 3 days prior to the first study drug. Patients with known untreated, asymptomatic brain metastases can be enrolled, but regular imaging assessments of the brain must be performed.
  16. There is a history of (non-infectious) pneumonia requiring steroid therapy or the presence of interstitial lung disease 1 year before the first dose;
  17. There are active infections that require systemic treatment;
  18. Subjects who are unable or unwilling to receive folic acid or vitamin B12 supplementation;
  19. There are known cases of mental illness or substance abuse that may have an impact on compliance with the test requirements;
  20. A history of (HIV) infection (ie, HIV 1/2 antibody positive) is known.
  21. Untreated active ;

    Note: Controlled (treated) hepatitis B subjects also meet the inclusion criteria if the following criteria are met:

    At least 4 weeks of HBV (Hepatitis B virus) antiviral therapy must have been received prior to the first dose of study drug, and the HBV viral load is \<1000 copies/ml (200 IU/ml). Subjects who are receiving HBV therapy and have a viral load of \<1000 copies/ml (200 IU/ml) should receive antiviral therapy throughout the study treatment period.

    For subjects with anti-HBc (hepatitis B core antigen)(+), HBsAg(-), anti-HBs(-), and HBV viral load (-), prophylactic anti-HBV therapy is not required, but viral reactivation is closely monitored;

  22. Active (Hepatitis C virus)-infected subjects (HCV antibody positive and HCV-RNA levels above the lower limit of detection);
  23. Vaccination of within 30 days before the first dose (1st cycle, 1st day); Note: Inactivated virus vaccines for seasonal influenza, injectable drugs are permitted; however, live attenuated influenza vaccines (such as FluMist®) are not allowed for intranasal administration;
  24. There may be a history of illness or disease evidence, treatment or laboratory abnormalities that may interfere with the subject's full participation in the study, or the investigator believes that participating in the study is not in the best interests of the subject, including dialysis.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
397 participants (actual)

Study arms

  • Experimental
    Sintilimab in combination with pemetrexed and platinum

    Injection; dosage form: 10ml: 100mg; frequency: 200mgQ3W (qualer 3 weeks); duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria Sintilimab 200mg + pemetrexed/ platinum 4 cycles then Sintilimab 200mg + pemetrexed maintains

    Drug: Sintilimab · Drug: Pemetrexed · Drug: Platinum

  • Placebo comparator
    Sitilimab Placebo Comparator

    placebo 2 vials + pemetrexed/ platinum 4 cycles then Sintilimab 200mg + pemetrexed maintains

    Drug: Pemetrexed · Drug: Platinum · Drug: Placebos

Interventions

  • 10 mL:100 mg,200mg,Q3W (qualer 3 weeks), day1, I.V.

    Also known as: IBI308

  • 500mg/m\^2; Q3W (qualer 3 weeks), day1, I.V.

  • Q3W (qualer 3 weeks), day1, I.V.; first 4 cycles.

  • DrugPlacebos

    10 mL:100 mg,200mg,Q3W (qualer 3 weeks), day1, I.V.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Independent Radiographic Review Committee (IRRC)

    PFS was defined as the time from randomization to the first documented PD or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD

    Time frame: Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)

Secondary outcomes

  1. Overall Survival (OS)

    The analysis population consisted of all randomized participants.

    Time frame: Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)

  2. Objective Response Rate (ORR) by IRRC Assessment

    ORR was defined as the percentage of participants in the analysis population who had a confirmed CR (disappearance of all lesions) or PR (at least a 30% decrease in the sum of diameters \[SOD\] of target lesions, taking as reference the baseline SOD) according to RECIST 1.1, which was modified for this study to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. The percentage of participants who experienced a confirmed CR or PR according to RECIST 1.1 as assessed by IRC was reported as the ORR

    Time frame: Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)

  3. Disease Control Rate (DCR) by IRRC Assessment

    Time frame: Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)

  4. Time to Response (TTR) by IRRC Assessment

    TTR was defined as the time of participants from the first treatment administration to the first incidence of a confirmed CR (disappearance of all lesions) or PR (at least a 30% decrease in the sum of diameters \[SOD\] of target lesions, taking as reference the baseline SOD) according to RECIST 1.1, which was modified for this study to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. The time from first treatment administration to the first incidence of treatment response was reported as the TTR

    Time frame: Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)

  5. Duration of Response (DOR) by IRRC Assessment

    Time frame: From time of first documented evidence of CR or PR trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)

07

Results

Posted Feb 16, 2021

Participant flow

Participant flow — Overall Study
MilestoneSintilimab CombinationPlacebo Combination
Started266131
Completed00
Not completed266131

Outcome measures

PrimaryProgression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Independent Radiographic Review Committee (IRRC)

PFS was defined as the time from randomization to the first documented PD or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD

Time frame:
Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)
Reported as:
Median · Months
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Independent Radiographic Review Committee (IRRC)
MonthsSintilimab CombinationPlacebo Combination
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Independent Radiographic Review Committee (IRRC)8.9 (7.1 to 11.3)5.0 (4.8 to 6.2)
SecondaryOverall Survival (OS)

The analysis population consisted of all randomized participants.

Time frame:
Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsSintilimab CombinationPlacebo Combination
Overall Survival (OS)NA (NA to NA)NA (11.4 to NA)
SecondaryObjective Response Rate (ORR) by IRRC Assessment

ORR was defined as the percentage of participants in the analysis population who had a confirmed CR (disappearance of all lesions) or PR (at least a 30% decrease in the sum of diameters \[SOD\] of target lesions, taking as reference the baseline SOD) according to RECIST 1.1, which was modified for this study to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. The percentage of participants who experienced a confirmed CR or PR according to RECIST 1.1 as assessed by IRC was reported as the ORR

Time frame:
Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) by IRRC Assessment
Percentage of ParticipantsSintilimab CombinationPlacebo Combination
Objective Response Rate (ORR) by IRRC Assessment51.9 (45.70 to 58.02)29.8 (22.10 to 38.38)
SecondaryDisease Control Rate (DCR) by IRRC Assessment
Time frame:
Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)
Reported as:
Number · Percentage of Participants
Disease Control Rate (DCR) by IRRC Assessment
Percentage of ParticipantsSintilimab CombinationPlacebo Combination
Disease Control Rate (DCR) by IRRC Assessment86.8 (82.18 to 90.66)75.6 (67.30 to 82.65)
SecondaryTime to Response (TTR) by IRRC Assessment

TTR was defined as the time of participants from the first treatment administration to the first incidence of a confirmed CR (disappearance of all lesions) or PR (at least a 30% decrease in the sum of diameters \[SOD\] of target lesions, taking as reference the baseline SOD) according to RECIST 1.1, which was modified for this study to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. The time from first treatment administration to the first incidence of treatment response was reported as the TTR

Time frame:
Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)
Reported as:
Median · Months
Time to Response (TTR) by IRRC Assessment
MonthsSintilimab CombinationPlacebo Combination
Time to Response (TTR) by IRRC Assessment1.51 (1.2 to 7.0)2.63 (1.2 to 5.1)
SecondaryDuration of Response (DOR) by IRRC Assessment
Time frame:
From time of first documented evidence of CR or PR trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)
Reported as:
Median · Months
Duration of Response (DOR) by IRRC Assessment
MonthsSintilimab CombinationPlacebo Combination
Duration of Response (DOR) by IRRC AssessmentNA (7.98 to NA)5.52 (4.14 to 10.94)

Adverse events

Collected over Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sintilimab Combination51/266 (19.2%)75/266 (28.2%)265/266 (99.6%)
Placebo Combination39/131 (29.8%)39/131 (29.8%)131/131 (100%)
Most frequent serious events
Showing 10 of 84
Most frequent serious events
EventSintilimab CombinationPlacebo Combination
Platelet count decreasedInvestigations12/2668/131
PneumoniaInfections and infestations7/2666/131
AnaemiaBlood and lymphatic system disorders12/2664/131
Immune-mediated pneumonitisRespiratory, thoracic and mediastinal disorders6/2661/131
PneumonitisRespiratory, thoracic and mediastinal disorders5/2660/131
Hepatic function abnormalHepatobiliary disorders5/2660/131
Neutrophil count decreasedInvestigations3/2662/131
White blood cell count decreasedInvestigations3/2662/131
Upper respiratory tract infectionInfections and infestations0/2662/131
Cerebral infarctionNervous system disorders0/2662/131
Most frequent other events
Showing 10 of 56
Most frequent other events
EventSintilimab CombinationPlacebo Combination
AnaemiaBlood and lymphatic system disorders197/266103/131
Neutrophil count decreasedInvestigations189/26682/131
White blood cell count decreasedInvestigations180/26684/131
Platelet count decreasedInvestigations113/26641/131
NauseaGastrointestinal disorders108/26655/131
Aspartate aminotransferase increasedInvestigations109/26651/131
Alanine aminotransferase increasedInvestigations108/26651/131
Decreased appetiteMetabolism and nutrition disorders101/26641/131
AstheniaGeneral disorders87/26642/131
ConstipationGastrointestinal disorders71/26642/131

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Sintilimab CombinationPlacebo CombinationTotal
Mean59.9 ± 8.3559.5 ± 8.7359.8 ± 8.47
Sex: Female, Male
Sex: Female, Male(Participants)Sintilimab CombinationPlacebo CombinationTotal
Female623294
Male20499303
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sintilimab CombinationPlacebo CombinationTotal
American Indian or Alaska Native000
Asian266131397
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Programmed Cell Death-Ligand(PD-L1) Tumor Proportion Score(TPS)
Programmed Cell Death-Ligand(PD-L1) Tumor Proportion Score(TPS)(Participants)Sintilimab CombinationPlacebo CombinationTotal
PD-L1 <1% (measured by the tumor proportion score [TPS])8544129
PD-L1 ≥ 1% (measured by the tumor proportion score[TPS])18187268
Platinum Chemotherapy
Platinum Chemotherapy(Participants)Sintilimab CombinationPlacebo CombinationTotal
Cisplatin7133104
Carboplatin19598293
08

Study locations

1 site
  • Sun Yat-Sen University Cancer Center
    Guangzhou, China
09

References and documents

Publications

  • Liu T, He J, Wang Y, Yang Y, Zhang L, Shi M, Liu J, Sun D, Wang Z, Fang J, Yu Q, Han B, Cang S, Chen G, Mei X, Yang Z, Huang Y, Fang W, Yang Y, Zhao Y, Zhang L. Health-related quality of life and symptoms in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer treated with sintilimab or placebo plus pemetrexed and platinum (ORIENT-11): A randomized, double-blind, phase 3 trial. Lung Cancer. 2025 Feb;200:108108. doi: 10.1016/j.lungcan.2025.108108. Epub 2025 Jan 27. PubMed 39884222 ↗
  • Liu Z, Yao Y, Zhao M, Zhao Q, Xue J, Huang Y, Qin S. Radiomics Models Derived From Arterial-Phase-Enhanced CT Reliably Predict Both PD-L1 Expression and Immunotherapy Prognosis in Non-small Cell Lung Cancer: A Retrospective, Multicenter Cohort Study. Acad Radiol. 2025 Jan;32(1):493-505. doi: 10.1016/j.acra.2024.07.028. Epub 2024 Jul 31. PubMed 39084935 ↗
  • Zhang L, Wang Z, Fang J, Yu Q, Han B, Cang S, Chen G, Mei X, Yang Z, Stefaniak V, Lin Y, Wang S, Zhang W, Sun L, Yang Y. Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study. Lung Cancer. 2022 Sep;171:56-60. doi: 10.1016/j.lungcan.2022.07.013. Epub 2022 Jul 19. PubMed 35917647 ↗
  • Yang Y, Wang Z, Fang J, Yu Q, Han B, Cang S, Chen G, Mei X, Yang Z, Ma R, Bi M, Ren X, Zhou J, Li B, Song Y, Feng J, Li J, He Z, Zhou R, Li W, Lu Y, Wang Y, Wang L, Yang N, Zhang Y, Yu Z, Zhao Y, Xie C, Cheng Y, Zhou H, Wang S, Zhu D, Zhang W, Zhang L. Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11). J Thorac Oncol. 2020 Oct;15(10):1636-1646. doi: 10.1016/j.jtho.2020.07.014. Epub 2020 Aug 8. PubMed 32781263 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Nov 2019, 14 months.

Results were first posted in Feb 2021, 1 year 3 months after primary completion.

Of 62 industry-sponsored phase 3 interventional studies under Lung Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 44. This study's 14 months is below that.

Counting every sponsor, half of 128 studies reached it within 44 months; a quarter within 30 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2018
First posted
Jul 31, 2018
StartActual
Aug 23, 2018
Primary completionActual
Nov 15, 2019
CompletionActual
May 31, 2022
Results first posted
Feb 16, 2021
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03607539
Responsible party
Sponsor
First posted
Jul 31, 2018
Start date
Aug 23, 2018
Primary completion
Nov 15, 2019
Completion
May 31, 2022
Results posted
Feb 16, 2021
Last update
May 11, 2026

Study contacts

Li Zhang, Doctor
principal investigator · SunYat-senUniversity

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sintilimab

Start the discussion